Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibodutant in Female Patients with IBS-D (IRIS-05)
NCT02320318Phase 3Withdrawn
- Sponsor
- Menarini Group
- Start
- Oct 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of ibodutant in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by Menarini Group. Planned start Oct 2015; status: withdrawn.
02
Drugs
ibodutant
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT02320318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320318.